AIA Group Ltd Has $12.31 Million Stock Position in Pfizer Inc. $PFE

AIA Group Ltd grew its position in Pfizer Inc. (NYSE:PFE) by 137.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 483,248 shares of the biopharmaceutical company’s stock after acquiring an additional 279,705 shares during the quarter. AIA Group Ltd’s holdings in Pfizer were worth $12,313,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer in the third quarter valued at $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer during the second quarter worth $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer during the second quarter worth $32,000. Evelyn Partners Asset Management Ltd bought a new stake in Pfizer in the 2nd quarter valued at $33,000. Finally, True Wealth Design LLC increased its holdings in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase‑2 win for atirmociclib: Pfizer reported positive topline results from the randomized FOURLIGHT‑1 study showing its next‑generation CDK4 inhibitor plus fulvestrant met the primary endpoint and reduced risk of progression or death (~40%). The result strengthens Pfizer’s oncology pipeline and positions atirmociclib as a potential successor/competitive option to existing CDK4/6 therapies. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Analyst upgrade/price‑target raise: HSBC raised its price target on PFE to $32 and maintained a Buy rating, giving investors an incremental valuation tailwind and signaling analyst confidence in Pfizer’s medium‑term outlook. HSBC Raises Price Target on Pfizer
• Neutral Sentiment: Early liver program progress: Pfizer advanced a Phase‑1 study of PF‑07328948 (liver indication), an early readout that modestly adds breadth to the pipeline but is unlikely to drive material near‑term revenue given its very early stage. Pfizer Advances Early PF-07328948 Liver Study
• Neutral Sentiment: Market/commentary noise: Media/analyst chatter (including TV commentary and bullish opinion pieces) is drawing attention to Pfizer’s broad pipeline and long‑term potential, but these are sentiment drivers rather than new clinical or commercial facts. Expect short‑term volatility around headlines. Jim Cramer Notes Pfizer Has “Got a Lot of Stuff in the Pipeline”
• Negative Sentiment: Study termination in melanoma: Pfizer ended a Phase‑1 study of PF‑08046031 in early‑stage melanoma, trimming one oncology program. While not expected to be material to top‑line forecasts, it marginally reduces pipeline optionality and is a near‑term negative datapoint for investors focused on oncology depth. Pfizer Ends Early-Stage Melanoma Study

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.33 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a 50 day simple moving average of $26.61 and a 200 day simple moving average of $25.57. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The firm has a market cap of $155.38 billion, a P/E ratio of 20.09 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PFE. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Monday, March 2nd. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $28.14.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.